SCHEMBL25282921

SCHEMBL25282921

FC(F)(F)c1cc2ccccc2c(S)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
HSD17B10 Q99714 3/20 0.39
KDM4E B2RXH2 2/20 0.39
TLR7 Q9NYK1 1/20 0.38
ADRB2 P07550 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 2/20 0.37
HPGD P15428 2/20 0.37
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
BACE1 P56817 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HIF1A Q16665 1/20 0.35
CYP1B1 Q16678 1/20 0.35
PDPK1 O15530 2/20 0.35
TRPV4 Q9HBA0 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
GRM4 Q14833 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31202588 1.00 ADORA2A (0.41) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL3293342 0.78 ADORA2A (0.41) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL30277306 0.78 ADORA2A (0.41) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL31631613 0.77 KDM4E (0.46) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL5660020 0.77 NT5E (0.41) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL12145214 0.77 KDM4E (0.46) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL639630 0.77 KMT2A (0.50) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL638693 0.73 TLR7 (0.38) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL27628904 0.70 TLR7 (0.43) ADORA2AADORA1HSD17B10KDM4ETLR7
SCHEMBL13542119 0.69 TRPM4 (0.45) HSD17B10KDM4EKMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421222-B2 Substituted quinazolines as HDAC6 inhibitors AUGUSTINE THERAPEUTICS (BE) 2025-09-23 US disclosed
US-20250145604-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2025-05-08 US disclosed
US-20250051319-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2025-02-13 US disclosed
EP-4452265-A2 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2024-10-30 EP disclosed
WO-2023118507-A2 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051319-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS HDAC6, HDAC9, HDAC1 ADORA2A 4698/4885ADORA1 4645/4885HSD17B10 408/4885
US-20250145604-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS HDAC6, HDAC9, HDAC1 ADORA2A 4698/4885ADORA1 4645/4885HSD17B10 408/4885
US-12421222-B2 Substituted quinazolines as HDAC6 inhibitors HDAC6, HDAC9, HDAC1 ADORA2A 4599/4885ADORA1 4485/4885HSD17B10 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.